Clinical Trial Update: A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TC-5214 as adjunct therapy for major depressive disorder has completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• TC-5214 (TC-5214)

Snippet

Sponsor: AstraZeneca | Conditions: Major Depressive Disorder, Depression | Phase 3 | Status: COMPLETED | Results posted: 2012-11-20